Press Releases

Makati City, Philippines — The European Chamber of Commerce of the Philippines (ECCP) recently hosted Food and Drug Administration Director General Paolo Teston for a high-level luncheon dialogue with industry leaders from the healthcare, food, and consumer sectors.

On 3 March 2026, the meeting went beyond routine policy updates and highlighted a shift toward regulatory reform and stronger institutional frameworks. Industry representatives from ECCP member companies welcomed the FDA’s reform initiatives and appreciated the agency’s willingness to engage in open dialogue with the private sector.

The discussion underscored how healthcare, food security, and consumer protection are not merely compliance matters; they are foundational pillars of economic growth. As the Philippines pursues inclusive development, the strength and predictability of its regulatory institutions will increasingly shape investor confidence, innovation timelines, and patient access to essential products.

The message from FDA leadership was clear: reform is underway and it is deliberate.

From Backlogs to Structural Reform

Director General Teston reported improvements in application processing timelines, noting productivity gains even with unchanged evaluator headcount. He pointed to internal performance indicators showing improvements in output, with some metrics reflecting gains of around 20 percent. Digitalization initiatives are being accelerated, while risk-based classification systems continue to be refined.

Reliance pathways for products approved by mature regulatory authorities are likewise being reviewed to enhance efficiency without compromising regulatory safeguards. The FDA emphasized that addressing legacy backlogs must go hand in hand with preventing new ones.

Industry participants noted that these developments represent important progress toward strengthening regulatory predictability.

Predictability as an Investment Driver

For regulated industries, particularly pharmaceuticals, medical devices, and food products, predictability is essential for long-term investment planning.

As Director General Teston noted during the discussion: “Predictability is important to investors.”

European companies operating in the Philippines adhere to stringent global regulatory standards. Alignment with international best practices, including calibrated reliance mechanisms and clearer pathways for low-risk variations, can strengthen competitiveness while maintaining high safety standards.

Regulatory clarity ultimately shortens time to market, improves product availability, and supports better public health outcomes.

Institutionalizing Reform

One of the most significant initiatives discussed was the FDA’s Five-Year Development Plan, aimed at institutionalizing reform beyond leadership cycles and securing the resources needed to sustain modernization efforts.

In regulatory environments where leadership transitions can affect policy direction, institutional continuity becomes critical.

As Director General Teston emphasized: “We cannot have multiple directions at the FDA. The direction must remain the same.”

A long-term roadmap anchored in clear funding and structural reform signals that regulatory improvements are system-driven rather than personality-driven.

Enforcement and Integrity

Alongside modernization, the FDA underscored the importance of strong enforcement against counterfeit and falsified products. The agency continues to issue numerous public advisories and coordinate with law enforcement authorities to disrupt illegal distribution networks.

Director General Teston mentioned during the dialogue: “Counterfeiting kills.” 

Counterfeit products threaten both patient safety and legitimate businesses, underscoring the need for a regulatory system that is both enabling and uncompromising.

Dialogue as Policy Infrastructure

The luncheon, moderated by ECCP Vice President Dr. Diana Edralin and Helen Grace Baisa, Chair of the ECCP Food and Beverage Committee, highlighted the value of structured engagement between regulators and industry stakeholders.

Participants welcomed the FDA’s openness to continued dialogue and technical consultations, recognizing that effective regulation benefits from insights from both regulators and the regulated sectors.

The ECCP reaffirmed its commitment to constructive collaboration with government partners, providing technical expertise, global benchmarks, and policy recommendations that support regulatory efficiency while safeguarding public health.

The Road Ahead

Regulatory modernization has the potential to unlock deeper participation in global value chains, attract higher-value investments, and accelerate patient access to innovation.

Reform is rarely instantaneous. But the signals matter.

Digital systems are being strengthened. Reliance pathways are under review. Backlogs are being addressed. A long-term development roadmap is being institutionalized.These are not isolated adjustments, they are building blocks toward a more predictable, transparent, and science-based regulatory environment.

In the end, regulation and industry are not opposing forces. They are partners in building public trust and economic resilience. And a predictable regulatory environment is not only good governance. It is national competitiveness in action.

The success of the ECCP Luncheon Meeting with FDA was made possible through the support extended by Event Supporter Jollibee Group and Table Top Partner Villa Medica Philippines (VMP) Regenerative Clinic.